Related references
Note: Only part of the references are listed.TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability
Surbhi Chouhan et al.
AUTOPHAGY (2023)
Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Ruchi Ghildiyal et al.
CANCER RESEARCH (2022)
Lipid Alterations in African American Men with Prostate Cancer
Anindita Ravindran et al.
METABOLITES (2022)
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Xiangnan Guan et al.
NATURE (2022)
Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer
Hyunwoo Kwon et al.
SCIENCE IMMUNOLOGY (2022)
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
Dhivya Sridaran et al.
NATURE COMMUNICATIONS (2022)
Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
Mithila Sawant et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Nicolo Pernigoni et al.
SCIENCE (2021)
KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer
Dingheng Lu et al.
CELL DEATH & DISEASE (2021)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Sumit K. Subudhi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N. Graff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Past, Current, and Future of Immunotherapies for Prostate Cancer
Adeline N. Boettcher et al.
FRONTIERS IN ONCOLOGY (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J. Khalaf et al.
LANCET ONCOLOGY (2019)
Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway
Hyeon Jeong Lee et al.
MOLECULAR CANCER RESEARCH (2018)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Ming Chen et al.
NATURE GENETICS (2018)
Androgen-Induced Immunosuppression
Melanie R. Gubbels Rupp et al.
FRONTIERS IN IMMUNOLOGY (2018)
Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder
Danthasinghe Waduge Badrajee Piyarathna et al.
EUROPEAN UROLOGY FOCUS (2018)
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Hitoshi Shimano et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer
Bi-Dar Wang et al.
NATURE COMMUNICATIONS (2017)
ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer
Kiran Mahajan et al.
CANCER CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database
Emma H. Allott et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer
Li Zhang et al.
CANCER RESEARCH (2016)
Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation
Isabel R. Schlaepfer et al.
ONCOTARGET (2015)
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer
Lauren C. Harshman et al.
JAMA ONCOLOGY (2015)
Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness
Shuhua Yue et al.
CELL METABOLISM (2014)
Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling
Xiangyan Li et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth
Beatrice Griffiths et al.
CANCER & METABOLISM (2013)
Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer
Kiran Mahajan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
The impact of FADS genetic variants on ω6 polyunsaturated fatty acid metabolism in African Americans
Rasika A. Mathias et al.
BMC GENETICS (2011)
Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study
G. David Batty et al.
CANCER CAUSES & CONTROL (2011)
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Changmeng Cai et al.
CANCER RESEARCH (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation
Qihuang Jin et al.
EMBO JOURNAL (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gcn5 and SAGA Regulate Shelterin Protein Turnover and Telomere Maintenance
Boyko S. Atanassov et al.
MOLECULAR CELL (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A. Locke et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol
Paulette R. Dillard et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Model-based Analysis of ChIP-Seq (MACS)
Yong Zhang et al.
GENOME BIOLOGY (2008)
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score
Tsutomu Nishiyama et al.
JOURNAL OF UROLOGY (2007)
Epidemiology and pathophysiology of prostate cancer in African-American men
Isaac J. Powell
JOURNAL OF UROLOGY (2007)
Protein sensors for membrane sterols
JL Goldstein et al.
CELL (2006)
Hypertriglyceridemia as a possible risk factor for prostate cancer
L Wuermli et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer
T Nishiyama et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
